Want to see AU:AGN full AI Analyst Report?
Top Page
Argenica Therapeutics Ltd
(Sydney:AGN)
Select Model
Select Model
Rating:52Neutral
Price Target:
AU$0.19
▼(-4.00% Downside)
Action:Reiterated
Date:08/27/26
The score is held back primarily by weak financial performance—unstable/vanishing recent revenue, persistent losses, and ongoing operating cash burn implying continued funding reliance—despite the benefit of a debt-free balance sheet. Technicals are moderately supportive with price above shorter-term moving averages and positive momentum, while valuation remains difficult to justify given negative earnings and no dividend support.
Positive Factors
Debt-Free Balance Sheet
Zero debt limits leverage-related stress and preserves financial flexibility as the company funds research and development. This provides a stronger foundation than a similarly loss-making biotech carrying material borrowings.
Negative Factors
Revenue Volatility
A return to zero revenue indicates that commercial activity is not yet dependable. Such volatility limits revenue visibility, weakens operating leverage, and leaves the company reliant on future licensing, partnerships, or successful product development.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
Zero debt limits leverage-related stress and preserves financial flexibility as the company funds research and development. This provides a stronger foundation than a similarly loss-making biotech carrying material borrowings.
Read all positive factors
Argenica Therapeutics Ltd (AGN) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$25.05M
Dividend YieldN/A
Average Volume (3M)115.91K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue GrowthN/A
EPS Growth81.00%
CountryAU
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.08
Shares Outstanding128,456,710
10 Day Avg. Volume73,134
30 Day Avg. Volume115,914
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)AU$28.10M
Argenica Therapeutics Ltd Business Overview & Revenue Model
Company Description
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clin...
How the Company Makes Money
null...
Argenica Therapeutics Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 379.87K | 0.00 | 3.21M | 2.60M | 1.75M | 259.10K |
| Gross Profit | 379.87K | 0.00 | 3.21M | 2.60M | 1.75M | 259.10K |
| EBITDA | -4.54M | -7.06M | 0.00 | -1.90M | -4.81M | -4.09M |
| Net Income | -9.80M | -1.37M | -7.17M | -5.48M | -4.82M | -4.09M |
Balance Sheet | ||||||
| Total Assets | 5.20M | 6.52M | 11.04M | 16.38M | 9.54M | 9.04M |
| Cash, Cash Equivalents and Short-Term Investments | 5.04M | 6.36M | 10.56M | 15.91M | 9.34M | 8.91M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.76M | 614.55K | 3.80M | 2.43M | 1.87M | 735.91K |
| Stockholders Equity | 3.44M | 5.90M | 7.24M | 13.95M | 7.67M | 8.31M |
Cash Flow | ||||||
| Free Cash Flow | -10.04M | 0.00 | -5.70M | -5.06M | -3.30M | -3.36M |
| Operating Cash Flow | -10.04M | -4.19M | -5.70M | -5.06M | -3.30M | -3.36M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 50.00K | -50.00K | 0.00 |
| Financing Cash Flow | 3.19K | -2.94K | 346.90K | 11.63M | 3.73M | 5.13M |
Argenica Therapeutics Ltd Technical Analysis
Neutral
0.20
Price Trends
0.16
Positive
0.15
Positive
0.20
Negative
Market Momentum
<0.01
Positive
48.12
Neutral
30.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AGN, the sentiment is Neutral. The current price of 0.2 is above the 20-day moving average (MA) of 0.19, above the 50-day MA of 0.16, and above the 200-day MA of 0.20, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.12 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:AGN.
Argenica Therapeutics Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$25.05M | -16.98 | -29.22% | ― | ― | 81.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$11.48M | -2.74 | -164.96% | ― | -4.24% | 33.39% | |
47 Neutral | AU$57.47M | -0.62 | -118.74% | ― | 499.47% | 31.20% | |
46 Neutral | AU$5.44M | -1.02 | -52.04% | ― | 32.22% | -26.53% | |
43 Neutral | AU$22.30M | -10.00 | -88.14% | ― | ― | -200.00% | |
41 Neutral | AU$2.68M | -0.30 | -179.37% | ― | ― | 15.04% |
* Healthcare Sector Average
AU:AGN
Argenica Therapeutics Ltd
0.18
-0.07
-28.00%
AU:CYP
Cynata Therapeutics Limited
0.01
-0.19
-94.50%
AU:1AI
Living Cell Technologies
0.01
0.00
0.00%
AU:TRP
Tissue Repair Ltd
0.09
-0.19
-67.86%
AU:CMB
Regeneus Ltd.
0.45
-0.02
-5.26%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.11
-84.44%
Argenica Therapeutics Ltd Corporate Events
Argenica Files 2026 Corporate Governance Statement with ASX
Aug 26, 2026
Argenica Therapeutics Ltd has lodged its Appendix 4G and corporate governance statement for the financial year ended 30 June 2026, confirming compliance with ASX Listing Rules on governance reporting. The statement, current as of 26 August 2026, i...
Argenica Narrows Annual Loss as R&D Support Boosts Revenue
Aug 26, 2026
Argenica Therapeutics reported a 53% increase in revenue to $5.7 million for the year to 30 June 2026, driven mainly by a larger RD tax incentive rebate and higher government grant income, while narrowing its after-tax loss by 81% to $1.37 million...
Argenica Options Lapse Trims Potential Diluted Capital
Aug 13, 2026
Argenica Therapeutics has announced the cessation of 200,000 AGNAM options, which were due to expire in April 2029 with an exercise price of $0.42. The options lapsed because the conditions attached to these rights were not met or became incapable...
Argenica Highlights Neuroprotection Strategy in New Investor Briefing
Jul 26, 2026
Argenica Therapeutics has released an investor presentation outlining its strategy in precision neuroprotection for severe brain injury patients. The presentation, delivered by Managing Director Dr Liz Dallimore, positions the company’s lead...
WHO Confirms International Generic Name for Argenica’s Lead Stroke Drug
Jun 9, 2026
Argenica Therapeutics, a Perth-based clinical-stage biotech, is developing neuroprotective drugs to improve outcomes after stroke and acute neurological injuries, led by its candidate xaranetide (ARG-007) targeting the preservation of brain tissue...
Argenica Options Lapse Clarifies Capital Structure
Jun 9, 2026
Argenica Therapeutics has notified the market of the cessation of 1,000,000 AGNAK options, which expired on 9 June 2026 at an exercise price of $0.65 without being exercised or converted. The lapse of these options slightly reduces the companyR...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.